Fosun Pharma terminated the acquisition of the remaining 40.44% stake in Henlius for HKD5.4bn.

Fosun Pharma, a Chinese listed pharmaceutical company, terminated the acquisition of the remaining 40.44% stake in Henlius, a global biopharmaceutical company, for HKD5.4bn. As at the date of the termination announcement, Fosun Pharma (through its subsidiaries) holds an aggregate of 59.56% equity interest in the Company. Although the Merger will not be implemented, it will not affect Fosun Pharma’s controlling position in the Company, and the Company will continue to act as Fosun Pharma Group’s key platform for antibody technology.